CPRIT: Patient Adherence to Lung Cancer… | Clinical Trial

Key information

Conditions

Lung Cancer Screening

Age range

50 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location status: Recruiting

Location contact

Robert Volk, PHD

CONTACT

[email protected]

713-563-2509

About this study

Primary Objectives/Aims

Determine rates of lung cancer scheduling and screening at the UTMB and UT Tyler LCS programs.
Using state-of-the-art machine learning (ML) approaches, develop prediction models for adherence to screening guidelines for newly eligible and established patients. Investigators will leverage data from BRFSS, UT Tyler and UTMB to develop and validate the prediction model, ensuring its generalizability and accuracy.
Survey participants in the LCS programs about their impressions and experience with the scheduling and completing screening; conduct interviews with participants who receive an order for LCS but do not complete screening by their due date.
Interview LCS program directors and staff about barriers and facilitators of increasing screening rates in their programs.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Current smoker or quit within the past 15 years
A 20+ pack-year smoking history
Healthy enough for treatment

Exclusion criteria

Not applicable as our focus is on patients with an order for screening at the UTMB or UT Tyler

Treatment and study plan

Lung Cancer Screening

Behavioral

Participants who agree to take part in this study, will participate in an interview. During the interview, participants may be asked about: • Participants background information, such as your race and level of education • Participants lung cancer diagnosis and your history of lung cancer screening • Participants experience with scheduling lung cancer screening • Any barriers that kept participants from completing screening

Primary outcomes

Safety and Adverse Events (AEs)

Time frame: Through study completion; an average of 1 year.

Study contacts

Contact information is provided by the study sponsor or research team.

Robert Volk, PHD

CONTACT

[email protected]

713-563-2509

Sponsors and collaborators

Lead sponsor

M.D. Anderson Cancer Center

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2029
Study completion: 2031
First posted: Mar 12, 2025
Registry last updated: Apr 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting